Nitric oxide signalling in kidney regulation and cardiometabolic health

Mattias Carlström

Abstract | The prevalence of cardiovascular and metabolic disease coupled with kidney dysfunction is increasing worldwide. This triad of disorders is associated with considerable morbidity and mortality as well as a substantial economic burden. Further understanding of the underlying pathophysiological mechanisms is important to develop novel preventive or therapeutic approaches. Among the proposed mechanisms, compromised nitric oxide (NO) bioactivity associated with oxidative stress is considered to be important. NO is a short-lived diatomic signalling molecule that exerts numerous effects on the kidneys, heart and vasculature as well as on peripheral metabolically active organs. The enzymatic l-arginine-dependent NO synthase (NOS) pathway is classically viewed as the main source of endogenous NO formation. However, the function of the NOS system is often compromised in various pathologies including kidney, cardiovascular and metabolic diseases. An alternative pathway, the nitrate–nitrite–NO pathway, enables endogenous or dietary-derived inorganic nitrate and nitrite to be recycled via serial reduction to form bioactive nitrogen species, including NO, independent of the NOS system. Signalling via these nitrogen species is linked with cGMP-independent and independent mechanisms. Novel approaches to restoring NO homeostasis during NOS deficiency and oxidative stress have potential therapeutic applications in kidney, cardiovascular and metabolic disorders.

The prevalence of cardiovascular disorders, including hypertension, and metabolic disorders such as type 2 diabetes mellitus (T2DM), is increasing worldwide. These disorders are closely coupled with the development and progression of kidney disease, which significantly increases patient morbidity and mortality. The resulting societal economic burden is immense and further understanding of the underlying pathophysiological mechanisms is urgently needed to enable the development of novel preventive and therapeutic nutritional and pharmacological strategies. The kidney, cardiovascular and metabolic phenotypes (that is, kidney disease, cardiovascular disease and T2DM) are interrelated, suggesting that this triad of disorders share common underlying pathological mechanisms. The exact causes of these disorders, the interactions between organ systems and the complex pathophysiological mechanism(s) that underlie the initiation, maintenance and progression of disease are complex and not fully understood.

Potential mechanisms that might contribute to the development of kidney disease, cardiovascular disease and T2DM include hyperglycaemia, altered lipid metabolism, low-grade inflammation, overactivity of the renin–angiotensin–aldosterone system (RAAS), increased sympathetic nerve activity and altered microbiota. In addition, several studies have suggested a substantial contribution of increased generation of NADPH oxidase-derived and mitochondria-derived reactive oxygen species (ROS) and oxidative stress coupled with reduced nitric oxide (NO) bioactivity and endothelial dysfunction. NO is a short-lived diatomic signalling molecule that exerts multiple effects on kidney, cardiovascular and metabolic functions, including modulation of renal autoregulation, tubular fluid and electrolyte transport, vascular tone, blood pressure, platelet aggregation, immune cell activation, insulin-glucose homeostasis and mitochondrial function. The classical view is that nitric oxide synthase (NOS) systems are the main source of endogenous NO formation. However, an alternative pathway exists whereby the supposedly inert oxidation products of NO, that is, inorganic nitrate and nitrite, undergo serial reduction to form bioactive nitrogen species independent of the NOS system. Signalling via these nitrogen species is linked with cGMP-dependent and independent mechanisms. Novel approaches to restoring NO homeostasis during NOS deficiency and oxidative stress have potential therapeutic applications in kidney, cardiovascular and metabolic disorders.
**Key points**

- Nitric oxide and other bioactive nitrogen species have pivotal roles in multiple physiological functions, including modulation of the kidney, cardiovascular and metabolic systems; in the kidney, nitric oxide has a crucial role in autoregulation and modulation of tubular transport.
- Nitric oxide is classically derived from l-arginine-dependent nitric oxide synthases, but can also be formed via serial reduction of inorganic nitrate and nitrite, that is, the nitrate–nitrite–nitric oxide pathway.
- The nitrate–nitrite–nitric oxide pathway can be boosted via the diet and is of particular importance in conditions where the activity of the nitric oxide synthase system is reduced, such as hypoxia, ischaemia or low pH.
- Signalling via bioactive nitrogen species is linked with both cGMP-dependent and independent mechanisms.
- Reduced nitric oxide bioactivity has been associated with ageing and kidney, cardiovascular and metabolic disorders, which are often coupled with oxidative stress.
- Novel pharmacological and nutritional strategies that increase nitric oxide bioactivity and reduce oxidative stress could be potential therapies for preventing and treating kidney disease and associated cardiometabolic complications.

NOS deficiency with a focus on the alternative nitrate–nitrite–NO pathway, which can be boosted via dietary intake, particularly by eating green leafy vegetables.

**The classical NO synthase systems**

NO is endogenously generated by numerous cells throughout the body via three different NOS systems (Fig. 1). Neuronal NOS (nNOS; also known as NOS1) and endothelial NOS (eNOS; also known as NOS3) are constitutively expressed, whereas inducible NOS (iNOS; also known as NOS2) is mainly associated with inflammatory conditions. l-Arginine, molecular oxygen, NADPH and tetrahydrobiopterin (BH₄) are equally important substrates or co-factors that lead to equimolar generation of NO and l-citrulline.

In the endothelium, eNOS-derived NO has a central role in the regulation of blood flow and maintenance of endothelial integrity. The activity of eNOS and nNOS is regulated by intracellular calcium, which activates calmodulin. In turn, calmodulin binds and increases NOS enzyme activity. This process results in NO-mediated activation of soluble guanylate cyclase (sGC) and increased formation of cyclic GMP (cGMP), which activates cGMP-dependent protein kinases. This NO–sGC–cGMP signalling pathway mediates many of the effects of NO bioactivity on cardiovascular, kidney and metabolic functions.

However, other bioactive nitrogen oxide species formed by reactions of NO can induce other important physiological signalling pathways, including post-translational modifications of proteins, independent of cGMP signalling (Fig. 1). These bioactive nitrogen oxide species include mobile nitrosyl–heme (heme-NO)₂, dinitrosyl–iron complexes, S-nitrosothiols, nitrogen dioxide (NO₂)⁻, dinitrogen trioxide, nitrosopersulfides, nitrooxy and peroxynitrite. Oxidation of NO to form the more stable anions nitrite and nitrate also provides more distant NO-like bioactivity.

NOS are also modulated via complex post-translational modifications, including acylation, nitrosylation, phosphorylation, acetylation, glycosylation and glutathionylation at various sites, as well as via protein–protein interactions and regulation of subcellular localization, which can increase or decrease their enzymatic activity. Acute changes in nNOS and eNOS activity in the vasculature and the kidney are mainly modulated via post-translational mechanisms, whereas chronic changes in NO synthesis are regulated by altered eNOS or nNOS transcription and translation. Activation of iNOS is associated with inflammatory processes and leads to significantly higher levels of NO than those that are produced by constitutive activation of other NOS isoforms. The resulting acute increases in NO have beneficial antimicrobial effects against bacteria, viruses and fungi. However, induction of iNOS is also associated with chronic low-grade inflammation in cardiovascular, metabolic and kidney disorders.

The constitutive NOS systems are generally thought to be the main source of endogenous NO production and signalling under normal, healthy conditions, but are often dysfunctional in pathological conditions including cardiovascular disorders and chronic kidney disease (CKD). This dysfunction is associated with reduced NO bioactivity. The mechanisms that contribute to reduced NO formation and compromised signalling are multifactorial and include reduced NOS expression, limited substrate availability, uncoupling of NOS, elevated levels of endogenous NOS inhibitors such as asymmetric dimethylarginine and compromised signalling in states of oxidative stress due to direct scavenging by ROS or oxidation of the heme group in sGC (Fe²⁺ to Fe³⁺), which renders it insensitive to activation by NO.

**Kidney expression of NOS isoforms**

Expression of all three NOS isoforms and sGC has been reported in the kidney, although some discrepancies exist regarding the expression levels along the nephron, when comparing data from human and animal studies. Moreover, splice variants of nNOS and iNOS can influence their activity and function. In the macula densa, splice variants (α, β and γ isoforms) have been reported to have a substantial impact on the function of nNOS, thus regulating renin secretion and autoregulatory mechanisms.

Expression of NOS in the macula densa and eNOS in the kidney vasculature has been consistently documented; some but not all studies have also reported eNOS expression in tubular epithelial cells. In normal, healthy human kidney tissue samples, NOS protein and mRNA expression was detected in most segments of the nephron, including the macula densa, proximal tubule, thick ascending limb (TAL) of the loop of Henle, distal tubule and collecting duct. eNOS was only expressed in the endothelium and iNOS was not detected in any of the tested segments. The expression of NOS, which was confirmed using enzyme activity studies, was generally found to be higher in the cortex than in the medulla. Data from the Human Protein Atlas support these findings, indicating that NOS is expressed in cortical tubules but not in glomeruli and that eNOS is expressed in glomeruli but not in tubules. Moreover, iNOS is expressed at low levels in tubules but not in glomeruli. Whether or not constitutive iNOS

---

**Nitrosylation**

The formation of a nitrosyl species (X-NO, where X represents a metal centre or radical species) via a direct reaction with NO.
Nitration
The addition of a nitronium ion (NO$_2^+$) to a nucleophilic group, leading to the generation of an N-O$_2$ species (formation of a nitro group).

Transnitrosation
The transfer of NO$^+$ from one nucleophilic centre to another.

Transnitrosylation
The transfer of NO$^-$ from one molecule to another.

Myogenic response
The intrinsic capacity of small resistance arteries and arterioles to react (contract or dilate) in response to variations in blood pressure to keep the blood flow constant.

expression has a functional role in the healthy kidney is controversial, but a substantial body of evidence demonstrates increased iNOS expression and activity during pathological conditions associated with inflammation, such as ischaemia–reperfusion injury (IRI) and lipopolysaccharide-induced endotoxemia or sepsis and CKD.

The nitrate–nitrite–NO pathway
Redox reactions with other radicals and transition metals, such as those in heme proteins, rapidly metabolize NO to form other stable nitrogen oxide species, including nitrite and nitrate. As these anions are mainly excreted by the kidneys, the sum of their total urinary excretion (termed NOx) during a 24-h period has often been used to estimate whole-body NO activity. However, circulating nitrate and nitrite can also be converted back to bioactive NO species via endogenous serial reduction, that is, the nitrate–nitrite–NO pathway (Fig. 2).

Moreover, dietary intake contributes substantially to the body pool of nitrate and nitrite. Ingested nitrate that enters the circulation is actively taken up by the salivary glands and then concentrated and excreted in the saliva (this process is known as enterosalivary circulation of nitrate). Accumulating evidence shows that commensal bacteria in the oral cavity have a crucial role in the first step of the reduction of nitrate to nitrite. In the acidic gastric milieu, swallowed nitrite is rapidly protonated and non-enzymatically forms NO and other nitrogen species with nitrosating and nitrating properties.

In contrast to NO-dependent generation, the nitrate–nitrite–NO pathway is oxygen independent and potentiates during conditions of low oxygen tension (that is, hypoxia and ischaemia) and low pH. This effect can be explained by more efficient non-enzymatic reduction of nitrite by protonation under more acidic conditions. During hypoxic conditions, enhanced activity of enzymes such as XOR and the formation of deoxyhaemoglobin also contribute to increased bioactivity of NO by facilitating the reduction of nitrite, and potentially also nitrate, to NO.

In contrast to hypoxic conditions, low pH can also enhance the activity of enzymes such as XOR and the formation of deoxyhaemoglobin also contribute to increased bioactivity of NO by facilitating the reduction of nitrite, and potentially also nitrate, to NO. However, signalling by nitrate- and nitrite-derived bioactive species also occurs during normoxia in humans, as evidenced by blood pressure reduction and vasodilatation following treatment with nitrate and nitrite, respectively (discussed further below).

Role of NO in renal autoregulation
Renal autoregulatory mechanisms operate together to maintain relatively constant blood flow and glomerular filtration rate (GFR) despite variations in renal perfusion pressure over a wide range (80–180 mmHg). These mechanisms are crucial to prevent barotrauma.

Myogenic response and tubuloglomerular feedback
Autoregulation is largely mediated by the myogenic response, macula densa-derived tubuloglomerular feedback (TGF) and their interactions. Both mechanisms regulate pre-glomerular tone primarily via changes in the afferent arteriolar diameter, which is the effector site. Moreover, the tone and contractility of the afferent arterioles are modulated by the concentration and interaction of several endogenous vasoactive substances, including NO, angiotensin II (Ang II) and adenosine, within the juxtaglomerular apparatus, as well as by the activity of the sympathetic nervous system.

The mechanisms that contribute to myogenic and TGF responses and their complex interactions in health, hypertension, kidney disease and diabetes, involve changes in NO and ROS signalling. The myogenic

---

**Fig. 1 | The NOS pathway and potential effects of NO on cardiovascular, renal and metabolic functions.** Nitric oxide (NO) is endogenously formed by three different nitric oxide synthase (NOS) isoforms: neuronal NOS (nNOS), inducible (iNOS) and endothelial NOS (eNOS). The activity of these enzymes is oxygen dependent and requires L-arginine and several co-factors (calmodulin, nicotinamide adenine dinucleotide phosphate (NADPH), tetrahydrobiopterin (BH$_4$), flavin adenine dinucleotide (FAD) and flavin mononucleotide (FMN)). NO binds to the reduced heme site (Fe$^{2+}$) of soluble guanylyl cyclase (sGC), which activates this enzyme, leading to the formation of the second messenger cyclic GMP (cGMP) from GTP. NO is a short-lived molecule that is oxidized in blood and tissues to form nitrite (NO$_2^-$), nitrate (NO$_3^-$) and other bioactive nitrogen species.

---

**CARDIOVASCULAR EFFECTS**

- Vasorelaxation
- Endothelial function
- Angiogenesis
- Platelet aggregation
- Protein function
- Inflammation

**KIDNEY EFFECTS**

- GFR
- Myogenic response
- Tubuloglomerular feedback
- Nephropathy
- Tubular reabsorption
- Ang II
- Sympathetic nerve activity
- Oxidative stress

**METABOLIC EFFECTS**

- Insulin secretion
- Glucose clearance
- Beiging of fat
- Triglycerides
- Lipids
- Steatosis
- Mitochondrial efficiency
Circulating NO3
During conditions of normal oxygen tension and pH, NO and other bioactive nitrogen species are oxidized to form inorganic nitrite and nitrate in the blood and tissues. Circulating NO2− and NO3− can be reduced back to NO and other bioactive nitrogen species via non-enzymatic and enzymatic systems. This alternative pathway of NO generation is of particular importance during low oxygen tension (that is, ischaemia and hypoxia) and acidic conditions. In addition to NO-derived NO2−, which is formed following oxidation of NO, dietary inorganic nitrate is a major contributor to the pool of NO via a fundamentally different mechanism, the nitrate (NO3−)–nitrite (NO2−)–NO pathway.

**Fig. 2** The generation of bioactive NO in mammals. Nitric oxide (NO) is classically viewed to be formed via the NO synthase (NOS) pathway but can also be generated via a fundamentally different mechanism, the nitrate (NO3−)–nitrite (NO2−)–NO pathway. During conditions of normal oxygen tension and pH, NO and other bioactive nitrogen species are oxidized to form inorganic nitrite and nitrate in the blood and tissues. Circulating NO2− and NO3− can be reduced back to NO and other bioactive nitrogen species via non-enzymatic and enzymatic systems. This alternative pathway of NO generation is of particular importance during low oxygen tension (that is, ischaemia and hypoxia) and acidic conditions. In addition to NO-derived NO2−, which is formed following oxidation of NO, dietary inorganic nitrate is a major contributor to the pool of NO via a fundamentally different mechanism, the nitrate (NO3−)–nitrite (NO2−)–NO pathway.

[Diagram showing the generation of bioactive NO in mammals]

response and TGF as well as their interaction are modulated by NO3−-derived NO. The effects of non-selective and selective NOS inhibitors on renal autoregulation, mediated by the myogenic and TGF responses, have been assessed in various experimental models. In rat kidneys in vivo, the initial increase in renal vascular resistance during the first 5 s after an increase in perfusion pressure, which corresponds to the myogenic response, was greatly exaggerated in the setting of non-selective NOS inhibition26. However, no major effect of NOS inhibition was observed in the later phase (5–25 s) after an increase in perfusion pressure, corresponding to the TGF response. Another study in rats in vivo demonstrated that NOS inhibition reduced vascular conductance and augmented the myogenic response, as evidenced by a more abrupt reduction in vascular admittance gain (in the region corresponding to the myogenic response) and a steeper regression of vascular admittance on frequency27. Moreover, selective inhibition of nNOS in the macula densa did not induce substantial vasoconstriction but did potentiate the myogenic response, suggesting interaction between the two autoregulatory responses. In rat hydropnephrotic kidney preparations, which lack functional TGF, NOS inhibition had no effect on pressure-induced changes in afferent arteriole diameter (that is, the myogenic response)28. Ex vivo experiments using isolated and perfused single arterioles, showed no differences in afferent responses following increased perfusion pressure (that is, myogenic response) between vessels from eNOS knockout mice and wild-type controls29. Another study using in vitro blood-perfused juxtamedullary nephron preparations showed that inhibition of nNOS increased the arteriolar autoregulatory response to increased perfusion pressure.

These findings clearly indicate an important role of NO3−-derived NO in renal autoregulation. The contribution of eNOS versus nNOS in modulating myogenic responses is debated owing to differing findings depending on the experimental setting. However, the available data support a predominant role of macula densa nNOS-derived NO in dampening the speed and strength of the myogenic response30. The exact cellular events by which NO attenuates afferent arteriolar vascular smooth muscle cell contraction during myogenic responses are incompletely understood31. NO, cGMP or its target protein kinase G (PKG; also known as PRKG1) and cyclic adenosine monophosphate or protein kinase A could dampen Ca2+ signalling or sensitivity, and thereby moderate arteriolar tone32,33, via multiple mechanisms, for example, by inhibiting voltage-operated calcium channels or transient receptor potential cation channels, by activating large-conductance calcium-activated potassium channels, by suppressing ADP-ribosyl cyclase activity and thus leading to reduced ryanodine receptor-mediated Ca2+ mobilization or by NO-mediated interaction and/or scavenging of ROS.

TGF mechanisms are largely activated by increased tubular sodium-chloride load at the macula densa, which increases the activity of the apical Na+-K+-2Cl− cotransporter (NKCC2; also known as SLC12A1) and in turn other tubular transporters, leading to ATP generation and/or metabolism and the formation of adenosine. The resulting activation of adenosine A1 receptors and/or purinergic P2y receptors on adjacent vascular smooth muscle cells stimulates calcium-dependent signalling and contraction of the afferent arteriole (REF. 34). The available evidence suggests that nNOS is largely expressed in macula densa cells and has a functional role in the regulation of TGF and in at least the short-term regulation of volume homeostasis35. Early in vivo microperfusion studies in rats showed that local pharmacological inhibition of NO in the macula densa was associated with decreased glomerular capillary pressure, indicating a sensitized and exaggerated TGF response36. This reduction in glomerular capillary pressure following NOS inhibition was abolished by simultaneous tubular administration of the NKCC2 blocker furosemide. Subsequent studies using different approaches (for example, ex vivo double microperfused JGA preparations37 and transgenic nNOS knockout mice38) provided further evidence that nNOS dampens TGF responses. Compromised nNOS function in the macula densa has been implicated in hypertension, kidney disease and diabetes39. Early experimental studies showed that spontaneously hypertensive rats and the Milan hypertensive strain of rats have abnormal nNOS function40,41 and that chronic inhibition of nNOS increased TGF sensitivity, reduced GFR and salt and water excretion and subsequently led to hypertension42. Although nNOS is expressed in...
the human kidney\textsuperscript{42}, its functional role during renal autoregulation in health and disease is still a largely unexplored field.

Overall, the physiological significance of interactions between the vascular and tubular mechanisms that mediate autoregulation in the kidney remains elusive. These interactions are influenced by the balance of positive and negative modulators of vasomotor tone of afferent arterioles, which can be generated by macula densa and tubular cells. NO influences renal myogenic response and TGF as well as their interactions, but the primary source of NO generation is still debated.

**Medullary blood flow and pressure natriuresis**

The kidney medulla is perfused from cortical arterioles and the vasa recta capillary system of juxtamedullary nephrons. Measurement of medullary blood flow is considerably more complex than measurement of cortical blood flow, which might partly explain the variable results regarding the efficiency of medullary autoregulation in different studies and species. The descending vasa recta are surrounded by contractile pericytes that can generate a myogenic response\textsuperscript{46}. Different autoregulatory responses have been described in human outer medullary descending vasa recta of different diameters. In large diameter segments, contractions were observed in response to increased luminal pressure, whereas no significant change was observed in those with a small diameter\textsuperscript{47}. The same study showed concentration-dependent constriction of descending vasa recta in response to Ang II. NOS inhibition has also been shown to induce constriction of isolated rat descending vasa recta; this vasoconstriction could be reversed by an NO donor or by pharmacological inhibition of oxidative stress using a NOX inhibitor or a superoxide dismutase mimetic\textsuperscript{48}.

Paracrine agents including NO, prostaglandins and ATP have been proposed to modulate medullary autoregulatory and pressure natriuretic responses. In rat juxtamedullary nephron preparations, inhibition of macula densa nNOS led to significant increases in afferent arteriolar myogenic contraction in response to increased perfusion pressure\textsuperscript{49,50,51}. By contrast, stimulation of NO production in these nephron preparations dampened pressure-induced contraction of cortical radial artery and afferent arterioles by reducing autoregulatory responses.

Two main hypotheses exist regarding the interactions between renal autoregulation and pressure natriuresis in response to increased renal perfusion pressure with excellent autoregulation of cortical blood flow in the presence or absence of efficient autoregulation of medullary blood flow. The major difference between these hypotheses concerns the mediating factor(s) and the relative importance of a primary change in renal cortical NO generation versus a primary change in medullary blood flow\textsuperscript{52,53}. In general, the slope of the natriuretic response to increased renal perfusion pressure is attenuated by inhibition of NOS. Moreover, increased RAAS activity, sympathetic nerve activity and excessive formation of ROS, especially in the kidney medulla, may inhibit pressure natriuresis.

Abnormal NO homeostasis coupled with increases in Ang II and ROS and anomalous renal autoregulation (either increased activity contributing to hypertension or decreased activity in the chronic state) have been demonstrated in experimental models of hypertension (for example, spontaneously hypertensive rat, Milan hypertensive strain of rat, Dahl salt-sensitive rat, Goldblatt renovascular hypertension, Ang II-induced hypertension, DOCA-salt hypertension, brown Norway rat), CKD (for example, reduced renal mass models) and T2DM (for example, obese Zucker diabetic rat and chronic high fat diet)\textsuperscript{54-56}. Together, these studies suggest that augmented renal autoregulation (in particular TGF) may contribute to the development of hypertension, whereas decreased renal autoregulation can lead to both hypertension-induced and diabetes-induced nephropathies.

**Modulation of sodium transport by NO**

Sodium and water homeostasis is mainly regulated via the actions of hormones (that is, aldosterone and vasopressin) in the kidney as well as Ang II and endothelin signalling. However, other endogenous compounds that do not circulate at high levels, such as NO, contribute substantially to the renal handling of sodium and water.

\begin{center}
\begin{figure}
\centering
\includegraphics[width=\textwidth]{fig3}
\caption{GMP-independent signalling via bioactive nitrogen species. The nitric oxide synthase (NOS) systems and serial reductions of nitrate (NO\textsuperscript{3-}) and nitrite (NO\textsuperscript{2-}) lead to the formation of nitric oxide (NO\textsuperscript{-}) and other bioactive nitrogen species. These species can undergo nitration or nitrosylation/nitrosylation reactions independent of cyclic GMP (cGMP) signalling and modify proteins, lipids, nucleosides and metals as well as induce transnitration, which can alter gene expression, receptor signalling, enzyme activity and mitochondrial function and elicit antioxidant, anti-inflammatory, anti-fibrotic and inotropic effects. DNIC, dinitrosyl–iron complexes; eNOS, epithelial NOS; heme-NO, nitrosyl-heme; iNOS, inducible NOS; N\textsubscript{2}O\textsubscript{3}, dinitrogen trioxide; nNOS, neuronal NOS; NO\textsuperscript{3-}, nitrogen dioxide; ONOO\textsuperscript{-}, peroxynitrite; SNO, S-nitrosothiols.}
\end{figure}
\end{center}
Nitric oxide (NO) is generally considered to inhibit tubular sodium reabsorption along the nephron. However, differing results have been obtained in acute and chronic conditions, in different experimental settings (in vivo versus ex vivo) and in different species. Moreover, the effects of NO on tubular sodium (Na\(^+\)) handling seem to be dependent on hormonal activity, particularly via interaction with the renin–angiotensin–aldosterone system. In the proximal tubule, neuronal NO synthase (nNOS) and endothelial NOS (eNOS)-derived NO has been reported to inhibit the basolateral sodium–potassium pump (Na\(^+/K^+\)-ATPase) and the apical sodium/hydrogen exchanger 3 (NHE3), as well as to modulate the activity of the basolateral Na\(^+/K^+\)-ATPase) and the apical sodium/hydrogen exchanger 3 (NHE3). In the thick ascending limb (TAL) of the loop of Henle, eNOS-derived NO inhibits NHE3 and may also inhibit the apical Na\(^+/K^+/2Cl^-\) cotransporter (NKCC2). eNOS-derived NO also inhibits NKCC2 in macula densa cells. Activation of nNOS in the macula densa can inhibit paracrine signalling mediated via adenosine triphosphate (ATP) and adenosine (ADO), which forms part of the tubuloglomerular feedback mechanism following activation of purinergic P2 receptors located on vascular smooth muscle cells in the afferent arteriole.

nNOS expression has been demonstrated in the distal tubule but the potential effects of NO on specific transporters in this segment of the nephron (for example, the Na\(^+/K^+\)-ATPase) are currently not clear. Finally, in collecting duct cells, nNOS-derived NO can inhibit the epithelial sodium channel (ENaC).

Given the short half-life of NO in vivo, its actions are mainly thought to be mediated via autocrine or paracrine signalling. However, NO might also act as an endocrine hormone\(^{20}\), potentially via heme-NO signalling\(^{24}\). As discussed above, NO in the kidney originates not only from eNOS in the vasculature but also from tubular epithelial nNOS and potentially iNOS during pathological conditions associated with inflammation. Early studies that used pharmacological approaches to investigate the specific role of NOS-derived NO on tubular function were sometimes difficult to interpret because non-selective inhibition of systemic NO generation increased blood pressure, reduced renal perfusion and impacted on renal autoregulatory mechanisms. However, subsequent studies using more selective pharmacological inhibitors or genetic knockout approaches demonstrated that NOS inhibition can reduce sodium and fluid excretion without inducing substantial haemodynamic changes\(^{25}\).

Along the nephron, approximately 67% of the filtered sodium load is reabsorbed in the proximal convoluted tubules; 25% in the TAL of the loop of Henle; 5% in the distal convoluted tubule, connecting tubule and initial collecting tubule; and 3% in the inner medullary collecting duct\(^{26}\). nNOS and/or eNOS-derived NO have been reported to inhibit the basolateral sodium-potassium-pump (Na\(^+/K^+\)-ATPase) in the proximal tubule, apical sodium/hydrogen exchanger 3 (NHE3; also known as SLC9A3) in the thick ascending limb (TAL) of the loop of Henle, and apical epithelial sodium channel (ENaC).
channel (ENaC) in the cortical collecting duct\(^{91,95}\) (FIG. 4). Although nNOS is expressed in the distal tubule, its potential role in modulating transporters in this part of the nephron (for example, the Na\(^+/\)Cl\(^–\) cotransporter (NCC; also known as SLC12A3)) is not clear.

Early studies that used systemic administration of NOS inhibitors support an inhibitory effect of NO on proximal tubular sodium reabsorption\(^{96,97}\). However, a 2014 study using isolated human proximal tubules demonstrated that Ang II dose–dependently stimulated proximal tubular sodium transport (as demonstrated by increased activity of NHE3 and the basolateral Na\(^+-\)HCO\(_3\)\(^–\) cotransporter) via NO–CGMP–mediated phosphorylation of ERK\(^{98}\). This study also showed that treatment with the NO donor sodium nitroprusside reduced sodium transporter activity in mouse and rat proximal tubules, but had the opposite effect in human proximal tubules. Further investigation is needed to understand the reason for this discrepancy and to clarify if similar phenomena exist for other transporters and in other segments of the nephron. The effect of NO on tubular reabsorption could potentially be concentration dependent and involve interaction with regulatory hormonal systems such as the RAAS. Although the effects of NO on proximal tubular reabsorption is debated, NO clearly has an important role in kidney physiology and compromised NO bioactivity is associated with kidney disease and associated cardiovascular and metabolic disorders\(^{30,31}\).

**Tubular handling of NO metabolites**

As mentioned above, NO is rapidly metabolized to form nitrite and nitrate, which are mainly excreted by the kidneys. Although urinary excretion of NOx is often reported, this measurement mainly reflects nitrate, which is found in plasma at almost 1,000-fold higher concentrations and has a substantially longer half-life than nitrite (\(t_{1/2} \sim 6\) h versus \(t_{1/2} \sim 30\) min); thus, it is much more stable in urine. As diet is a major contributor to the pool of circulating nitrate and nitrite in the body, accumulated excretion of NOx can only be used to estimate NOS function during strict dietary restrictions. Moreover, kidney NOS activity might substantially influence the total excretion of NOx, at least during high salt intake. Among mice fed a high salt diet, those with deletion of nNOS in the collecting duct had approximately 50% lower NOx excretion than controls and developed hypertension\(^{39}\).

Early studies in young, healthy volunteers showed that only 60% of orally administered \(^{15}\)N-nitrate was excreted in the urine as nitrate within 48 h, with minimal amounts (0.1%) excreted in the faeces\(^{39,40}\). A small amount of \(^{15}\)N labelled nitrate was also excreted as ammonia or urea in the urine (2–4%) and faeces (0.2%), but the handling and/or removal of the remaining dose (36–38%) is still not clear. Some nitrate is likely distributed to the muscle pool and elimination from the body via exhalation of nitrogen gas is also possible.

A small clinical study showed that healthy volunteers with normal kidney function (eGFR \(>60\) ml/min/1.73 m\(^2\)) had significantly higher fractional excretion of nitrate (median 16.3%; 95% CI 8.7–22.8) than patients with CKD and eGFR \(\leq 30\) ml/min/1.73 m\(^2\) (median 10.3%, 95% CI 9.6–4.4)\(^{100}\). In patients with CKD, renal nitrate clearance correlated positively with kidney function. Reduced fractional excretion of nitrate in patients with reduced eGFR was associated with increased plasma nitrate levels. These findings might be explained by altered glomerular filtration and tubular handling of nitrate during kidney disease, but could also be related to reduced NOS-derived bioactivity in patients with CKD, leading to reduced production of oxidized NO metabolites in the circulation to which the kidneys might adapt by reabsorbing more or secreting less nitrate.

A randomized controlled trial that investigated sex differences in renal nitrate handling in adults (\(n = 231\)) with elevated blood pressure reported that during dietary nitrate restriction, urinary nitrate concentration, amount of nitrate excreted, renal nitrate clearance and fractional excretion of nitrate were significantly lower in women than in men\(^{103}\). However, no association was observed between plasma nitrate concentration or fractional excretion of nitrate and GFR in either sex. Following high dietary nitrate intake for 5 weeks, fractional excretion of nitrate markedly increased and no sex differences in renal handling of nitrate were observed. This study suggests that tubular nitrate reabsorption might be higher in women than in men, but the underlying mechanisms warrant further investigation.

In the absence of intrarenal generation, the fractional excretion of nitrate correlates linearly with plasma levels and has been calculated to be approximately 3–10% in anesthetized dogs and rats, with major reabsorption taking place in the proximal tubules\(^{104,105}\). In healthy volunteers, inhibition of carbonic anhydrase using acetazolamide lowered proximal tubular reabsorption of nitrite and nitrate and increased their content in the urine, suggesting a role of carbonic anhydrase-dependent mechanisms in this reabsorption\(^{106}\). Evidence suggests that nitrate reabsorption also takes place in later segments of the nephron; clearance and stop-flow studies in dogs showed that inhibition of NKKC2 with furosemide reduced the tubular reabsorption of nitrate from 97% to 87% during inhibition of intrarenal NOS and from 90% to 84% without NOS inhibition\(^{107}\).

Another possible candidate for nitrate reabsorption is the chloride–bicarbonate exchanger pendrin (also known as SLC26A4), which is expressed in intercalated cells in the distal convoluted tubule, the connecting tubule and the cortical collecting duct\(^{108}\). In vitro studies have shown that pendrin expression is reduced in mouse cortical collecting ducts and connecting tubules in the presence of NO donors, and upregulated during inhibition of NOS\(^{109}\). Sialin (also known as SLC17A5) transports nitrate from the plasma into the salivary glands\(^{41}\). High apical expression of sialin has been reported in distal tubule cells\(^{110}\), suggesting that this transporter might also contribute to renal reabsorption of nitrate.

Most of the current knowledge regarding the tubular handling of nitrate and nitrite is based on the excretion of nitrate. Both of these anions are freely filtered in the glomeruli but whether similar tubular transport mechanisms exist for nitrate and nitrite along the nephron is unknown. Further studies are needed to identify nitrate
Fig. 5 | Strategies to restore NO bioactivity. Endogenous nitric oxide (NO) bioactivity originates from the classical NO synthase (NOS) pathway and the alternative nitrate (NO3)–nitrite (NO2)–NO pathway. Signalling via NO and other bioactive nitrogen species involves soluble guanylate cyclase (sGC)-dependent formation of cyclic GMP (cGMP) as well as cGMP-independent effects. Kidney, cardiovascular and metabolic disorders are associated with reduced NO production and/or signalling, which might result from increased production of reactive oxygen species (ROS) from NADPH oxidase (NOX), mitochondria or uncoupled eNOS owing to substrate or co-factor deficiency. Several approaches might increase NO bioactivity. First, increasing or restoring endogenous NOS activity by supplementing with L-arginine, L-citrulline or tetrahydrobiopterin (BH4), inhibiting arginase or blocking the endogenous NOS inhibitor asymmetric dimethylarginine (ADMA). Statins, novel modulators of the renin–angiotensin–aldosterone system (RAAS) and compounds that increase hydrogen sulfide (H2S) formation or signalling might also restore NOS activity. Second, inhalation of NO or inorganic NO2, treatment with organic nitrates that directly or indirectly increase NO generation independent of the NOS system or dietary supplementation with inorganic nitrate. Compared with inhalation of NO and organic nitrates, the dietary approach, using inorganic nitrate, has a more favourable pharmacokinetic and pharmacodynamic profile and is associated with lower risk of tolerance and adverse effects. Third, limiting NO metabolism, for example, by reducing the generation of ROS and thereby preventing scavenging of NO, for example, using novel antioxidants and NOX inhibitors. In addition, angiotensin-converting enzyme (ACE) inhibitors and angiotensin II type 1 receptor (AT1) antagonists, which block angiotensin II (Ang II) formation and signalling, respectively, might reduce mitochondrial and NOX-derived ROS generation. Another novel approach is to oppose classical Ang II signalling by targeting the ACE2–neutral endopeptidase (NEP)–Ang1–7–AT2–Mas receptor pathway using an ACE2 stimulator, AT1 receptor antagonist or Mas receptor agonist. Activation of this pathway has been associated with increased eNOS function. Finally, NO signalling can be facilitated by modulating downstream signalling pathways with NO gas or inorganic nitrite, hybrid drugs that attach a NO-releasing moiety to an existing pharmacological agent, increasing H2S signalling, treatment with organic nitrates or supplementation with inorganic nitrate or nitrite. Third, limiting NO metabolism, for example, by dampening oxidative stress and thereby preventing scavenging of NO, and fourth, facilitating downstream signalling pathways, for example, using phosphodiesterase inhibitors, sGC stimulators or sGC activators. Some of the existing and promising future approaches to increasing NO generation and signalling are discussed below.

Inhaled NO gas
Since the FDA approval of inhaled NO for the treatment of persistent pulmonary hypertension in neonates in 1999, this approach has been used off-label in various clinical settings. Concerns exist regarding chronic use of inhaled NO, especially in patients with multiple-organ failure, owing to the risks of methaemoglobin formation (due to binding of NO to haemoglobin, which reduces its oxygen-carrying capacity) and development of kidney dysfunction. A systematic review and
meta-analysis of randomized trials showed that NO inhalation therapy increased the risk of acute kidney injury (AKI) in patients with acute respiratory distress syndrome (ARDS) but not in non-ARDS populations. The underlying mechanisms likely involve modulation of pre- and post-glomerular arteriolar resistance and altered tubular handling of salt and water, which is supported by previous animal and human studies. Kidney function and markers of AKI should therefore be closely monitored in patients who require inhaled NO therapy.

**Organic nitrates**
Nitroglycerin (also known as glyceryl trinitrate) dilates venous capacitance vessels, aorta, medium-to-large coronary arteries and collaterals. This organic nitrate and structurally similar compounds were used to treat angina, acute myocardial infarction and severe hypertension even before the discovery of the role of NO in physiology. Chronic use of organic nitrates has been associated with tolerance and risk of adverse effects, including hypotension and endothelial dysfunction, which limit their therapeutic applications.

**Arginase inhibition**
The NOS isoforms compete for L-arginine with two other enzymes, arginase and arginine methyltransferase, which convert L-arginine into urea and L-ornithine or asymmetric dimethylarginine (ADMA), respectively. ADMA in turn inhibits NOS activity by directly competing with L-arginine for binding to NOS, leading to NOS uncoupling. Two isoforms of arginase exist; arginase 1 is primarily located in the cytoplasm of hepatocytes and red blood cells, whereas arginase 2 is located in the mitochondria of several tissues in the body, with high abundance in the kidney (Human Protein Atlas). Increased arginase activity and elevated ADMA levels, together with reduced NO synthesis, have been associated with endothelial dysfunction and increased cardiovascular risk in patients with CKD and DKD. Increased arginase inhibition has been shown to improve microvascular endothelial function in patients with coronary artery disease and T2DM.

Experimental studies have shown that dietary inorganic nitrate can decrease arginase expression and activity, which may contribute to the salutary effects of nitrate in cardiovascular and metabolic disease. Increased arginase 2 expression and activity have been associated with kidney failure, diabetic kidney disease (DKD) and hypertensive nephropathy, and favourable effects of arginase inhibition have been demonstrated in kidney disease models. Further studies are required to investigate the potential clinical benefits of attenuating arginase function in patients with kidney disease.

**H2S formation and signalling**
The signalling molecule H2S has many similarities with NO and affects a wide range of physiological functions, including modulation of cardiovascular, renal and metabolic systems. H2S is formed endogenously in most organs, including the kidney, via enzymatic and non-enzymatic reactions. Stimulation of H2S production might enhance the NO–sGC–cGMP–PKG pathway by increasing NO production and its downstream signalling. H2S can also increase eNOS activation via mechanisms that involve mobilization of intracellular Ca2+ and promotion of phosphorylation. In addition, H2S might increase NO production independent of NOS via stimulation of XOR-dependent reduction of nitrite to NO. H2S has also been shown to activate sGC and/or directly increase cGMP levels via inhibition of phosphodiesterase. The interactions and crosstalk that occur between the NO and H2S signalling systems are complex and involve formation of S/N-hybrid species. Treatment with slow-releasing H2S donors is associated with protective effects in animal models of cardiovascular, kidney, and metabolic diseases, but these results await further clinical translation.

**Phosphodiesterase inhibition**
cGMP is hydrolysed to guanosine monophosphate (GMP) by phosphodiesterase. To date, phosphodiesterase 5 (PDE5), which is expressed in various tissues including the cardiovascular and renal systems, has been the main focus of research, but other phosphodiesterase isoforms have also been suggested to modulate NO-mediated cGMP-dependent and independent signalling. PDE5 inhibitors block cGMP breakdown and thereby lead to increased or prolonged NO signalling. These compounds have been proven to lower blood pressure in preclinical and clinical studies and to exert kidney and cardiovascular protective effects in various experimental models of IRI, heart failure, CKD and DKD. PDE5 is highly expressed in the kidney (in the glomeruli, mesangial cells, cortical tubules and inner medullary collecting duct) and the kidney-protective effects of PDE5 inhibitors are thought to extend far beyond their antihypertensive effect. In 5/6 nephrectomized rats, 8 weeks of treatment with a PDE5 inhibitor initiated immediately after nephrectomy prevented the development of hypertension and ameliorated kidney injury and proteinuria. However, this profound kidney protection was lost if PDE5 inhibition was initiated at a later stage (that is, 4 weeks after nephrectomy) when proteinuria was already evident.

PDE5 inhibitors are currently clinically approved for the treatment of pulmonary hypertension, erectile dysfunction and lower urinary tract symptoms. However, promising preclinical and early clinical findings suggest that additional therapeutic indications could be possible in the future. For example, a phase II trial demonstrated that once daily treatment with a long-acting PDE5 inhibitor for 12 weeks decreased albuminuria in 256 patients with T2DM and overt nephropathy. Importantly, this kidney-protective effect was observed despite simultaneous treatment with RAAS blockers and independent of any changes in blood pressure or GFR.

**Modulation of sGC**
Small compounds that target sGC are currently used to treat patients with pulmonary hypertension, but novel sGC stimulators and activators might have therapeutic value in other cardiovascular and kidney disorders. For example, clinical trials have demonstrated favourable
effects of these agents in patients with heart failure with preserved ejection fraction\textsuperscript{138} or heart failure with reduced ejection fraction\textsuperscript{139}. In various preclinical models of kidney disease, including hypertensive and diabetic nephropathy, unilateral ureteral obstruction and acute glomerular nephritis, treatment with sGC stimulators and activators has consistently been associated with kidney-protective effects, as evidenced by improved creatinine clearance, reduced proteinuria and albuminuria, attenuated glomerulosclerosis and tubulointerstitial fibrosis, reduced infiltration of macrophages and preservation of podocyte health\textsuperscript{140}. These favourable effects seem to be largely independent of any blood pressure reduction and hence may be of therapeutic value in patients with CKD who are treated with RAAS blockers. In vitro mechanistic studies have indicated that many of the antifibrotic effects of sGC stimulators and activators are coupled with cGMP-mediated suppression of transforming growth factor-\(\beta\) (TGF\(\beta\))–phospho-SMAD3 signalling\textsuperscript{141}. Clinical trials are needed to extend these exciting preclinical findings to patients.

A randomized, double-blind, placebo-controlled, phase II study (NCT03217591) evaluated the safety and efficacy of the sGC stimulator praliciguat (IW-1973) in 140 patients with T2DM and albuminuria treated with RAAS inhibitors\textsuperscript{142}. Treatment with praliciguat was not significantly associated with a reduction in albuminuria from baseline to week 8 and week 12 (the primary efficacy outcome) compared with placebo (\(P = 0.17\)). However, differences in some of the exploratory end points, including reduction in blood pressure and metabolic variables, such as haemoglobin A1c and cholesterol, favoured praliciguat treatment and support further investigation of this agent in DKD.

**ACE2 activators, AT\(_2\) agonists and Mas receptor agonists**

The identification and characterization of new components and pathways has led to extensive revision of the classical view of the RAAS during the past 15 years\textsuperscript{143,144}. In addition to inhibiting angiotensin-\(-\)converting enzyme (ACE), Ang II type 1 receptor (AT\(_1\)) or the mineralocorticoid receptor, potential therapeutic approaches include stimulating ACE2 or activating AT\(_2\), or the Mas receptor. In contrast to ACE, which converts Ang I to Ang II, ACE2 convert Ang I and Ang II to Ang(1–7), which activates the Mas receptor. Ang II-mediated signalling via AT\(_1\) is associated with vasoconstriction and elevation of blood pressure, whereas activation of AT\(_2\) is associated with vasodilation and reduction of blood pressure. Accumulating evidence suggests that ACE2 activators, AT\(_2\) agonists and Mas receptor agonists have protective effects in models of cardiovascular, kidney and metabolic diseases via mechanisms that involve lowering oxidative stress, dampening inflammation and increasing NO bioactivity\textsuperscript{145,146}. These preclinical findings suggest novel therapeutic strategies (Fig. 5).

Notably, cardiovascular\textsuperscript{145}, kidney\textsuperscript{146} and metabolic\textsuperscript{147} diseases have been associated with increased risk of severe COVID-19 and adverse outcomes following infection with SARS-CoV-2. The virus uses ACE2 to enter host cells, which negatively impacts ACE2 function and might increase oxidative stress, reduce NO formation and signalling, alter immune cell function, impair endothelial function and induce coagulopathy\textsuperscript{148,149}. Therapeutic strategies that restore ACE2–Ang(1–7)–Mas receptor signalling pathways and inhalation of NO have therefore been suggested as potential treatments for COVID-19 (REF\textsuperscript{s}148,149).

**Inorganic nitrate and nitrite supplementation**

Stimulation of the nitrate–nitrite–NO pathway via supplementation with inorganic nitrate or nitrite, either via the diet or in pill form, might enhance NO bioavailability. This approach has potential therapeutic applications in cardiovascular, metabolic and kidney disorders. Moreover, inhaled inorganic nitrite therapy has been shown to be safe and potentially efficacious in adult patients with pulmonary hypertension, heart failure with preserved ejection fraction\textsuperscript{151}.

**Cardiovascular effects.** Considerable research efforts have focused on the cardiovascular effects of inorganic nitrate supplementation, including the effects on blood pressure, endothelial function and arterial stiffness. In 2006, the first study to report a blood pressure-lowering effect of nitrate supplementation in healthy adults showed that 0.1 mmol/kg per day of sodium nitrate reduced diastolic blood pressure by a mean of almost 4 mmHg (REF\textsuperscript{152}). A subsequent study that used an approximately threefold higher dose of dietary nitrate, in the form of beetroot juice, demonstrated a more pronounced blood pressure-lowering effect (i.e. mean reductions in systolic blood pressure of 10.4 mmHg and diastolic blood pressure of 8 mmHg), together with vasoprotective and antiplatelet properties of nitrate\textsuperscript{153}.

Several research groups have since confirmed the blood pressure-lowering effect of nitrate in healthy individuals. In two meta-analyses of these studies, systolic blood pressure was reduced by means of 4.1–4.8 mmHg and diastolic blood pressure was reduced by means of 1.7–2.0 mmHg (REF\textsuperscript{s}154,155). One of these meta-analyses also analysed the effect of nitrate intake on other cardiovascular risk factors and reported improved endothelial function, reduced arterial stiffness and reduced platelet aggregation with this intervention\textsuperscript{156}.

Numerous experimental studies using various cardiovascular disease models, which are often associated with kidney and metabolic dysfunction, have also demonstrated favourable cardiovascular effects following treatment with inorganic nitrate, including antihypertensive effects and improved endothelial function\textsuperscript{157,158}. The underlying mechanisms that contribute to such effects involve various organ systems and modulation of the RAAS, inhibition of arginine, restoration of eNOS function, dampening of sympathetic hyperactivity and anti-inflammatory and anti-oxidative effects\textsuperscript{159}.

A study in 15 patients with hypertension demonstrated that acute dietary nitrate intake improved endothelial function and significantly lowered systolic and diastolic blood pressure\textsuperscript{160}. The maximum blood pressure-lowering effect was observed approximately 3–4 h after nitrate ingestion, when plasma nitrite levels peaked, and the effect lasted for as long as 24 h. The first
two studies investigating the cardiovascular effects of chronic nitrate supplementation in patients with hypertension were conducted independently of each other in 2015 and generated conflicting results\(^{159,160}\). One study showed no significant reduction in blood pressure following 1 week of nitrate supplementation, whereas the other showed a sustained blood pressure reduction following daily dietary intake of nitrate compared with placebo during a 4-week period, without any signs of tachyphylaxis\(^{161}\). A 2020 study showed that daily intake of nitrate for 5 weeks, in the form of either leafy green vegetables or a nitrate pill, did not significantly lower blood pressure in adults with pre-hypertension or stage 1 hypertension compared with intake of a low-nitrate control diet\(^{161}\). These differing findings are unlikely to be due to differences in the daily dose of nitrate, which was similar in all three studies (approximately 0.1 mmol/kg/day), and cannot be explained by patient age, body mass index or gender. However, differences in the number of simultaneous antihypertensive drugs, patient demographics, nitrate intake in the placebo group and blood pressure at the time of initiation of nitrate supplementation might be contributing factors. Another clinical trial showed that once-daily nitrate supplementation (approximately 0.1 mmol/kg/day) for 6 weeks improved vascular function in patients with hypercholesterolaemia, which was associated with a mild reduction in blood pressure\(^{162}\). Potential effects of nitrate supplementation on metabolic and/or kidney functions were not reported in these clinical studies.

Arterial stiffness is associated with aging and is a major risk factor for cardiovascular events such as myocardial infarction and stroke. A systematic review and meta-analysis of randomized controlled trials was conducted to estimate the effects of repeated nitrate administration (at least 3 days) on peripheral and central blood pressure and arterial stiffness in healthy individuals and in patients at increased risk of cardiovascular disease owing to obesity, hypertension, peripheral artery disease, hypercholesterolaemia and/or heart failure\(^{163}\). Pooled data from 45 studies using approximately 500 mg nitrate per day showed significant reductions in systolic (mean −2.91 mmHg) and diastolic blood pressure (mean −1.45 mmHg). Analysis of data from three trials that measured central (aortic) blood pressure also showed significant reductions with nitrate supplementation (mean systolic −1.6 mmHg, mean diastolic −2.0 mmHg). However, the meta-analysis found no significant differences in the effects of nitrate supplementation on blood pressure between subgroups of patients with differing health status. Notably, the reductions in blood pressure with nitrate supplementation in this meta-analysis, and in meta-analyses of data from healthy individuals\(^{154,155}\), are comparable with those observed in trials of reduced sodium intake and of a Dietary Approaches to Stop Hypertension (DASH) diet\(^{164,165}\). Analysis of data from seven trials that measured augmentation index and pulse wave velocity showed no significant effects of nitrate administration on arterial stiffness\(^ {166}\). However, the researchers note that the number of available trials in individuals with additional cardiovascular disease risk factors (i.e. hypertension, diabetes or hyperlipidaemia) was relatively small and their analysis was likely underpowered to detect significant differences. More studies are required to draw reliable conclusions in these patient groups.

Overall, the current evidence for a long-term favourable cardiovascular effect of nitrate supplementation in patients with cardiovascular disease, including hypertension, is inconclusive. Hence, additional large clinical trials with different doses of nitrate would be desirable.

Metabolic effects. Impaired metabolic control with obesity and hyperglycaemia is closely coupled with increased risk of DKD, which involves complex glomerular and tubular mechanisms\(^{166,167}\). In addition to the well-documented therapeutic benefits of ACE inhibitors and Ang II receptor blockers in patients with kidney disease\(^{168,169}\), large clinical trials have shown that treatment with sodium/glucose co-transporter-2 (SGLT2) inhibitors can reduce albuminuria, risk of CKD progression and cardiovascular events in patients with T2DM and kidney disease\(^{70}\). The favourable effects of SGLT2 inhibition are unlikely to be solely mediated by improved glycaemic control. Experimental evidence suggests that they are likely the result of various glomerulotubular mechanisms\(^{170,171}\) such as modulation of the myogenic response and TGF-β as well as tubular reabsorption and potential modulation of renal sympathetic nerve activity\(^{172}\). These mechanisms could potentially also indirectly affect NO bioactivity.

Mice that lack eNOS develop hypertension\(^ {173}\) and features that resemble metabolic syndrome (i.e. hypertension, dyslipidaemia, insulin resistance and obesity)\(^ {174}\). In addition, eNOS deficiency in rodents is associated with kidney injury\(^ {175,176}\) and accelerated progression of CKD\(^ {177,178}\). Almost a decade ago, supplementation with dietary doses of nitrate was demonstrated to reverse features of metabolic syndrome in mice that lacked eNOS\(^ {179}\). Numerous experimental studies have since confirmed that nitrate supplementation has favourable metabolic effects, which involve modulation of mitochondrial function and oxidative stress, activation of AMP-activated protein kinase (AMPK) signalling and modulation of downstream targets including sterol regulatory element-binding protein 1, acetyl-CoA carboxylase, medium-chain specific acyl-CoA dehydrogenase, mitochondrial and peroxisome proliferator-activated receptor-γ coactivator 1α\(^ {180}\). A link between nitrate and/or nitrite supplementation and AMPK activation has also been demonstrated in experimental models of heart failure with preserved ejection fraction\(^ {182}\) and IRI of the heart\(^ {183}\) as well as in studies of the potential beneficial effects of this supplementation on longevity\(^ {184}\). Knowledge of the specific mechanism(s) of AMPK activation in different cell types (for example, hepatocytes, adipocytes, skeletal muscle cells and cardiomyocytes) is limited, but studies have suggested involvement of nitrate and/or nitrite-mediated modulation of energy sensing pathways, including inhibition of target of rapamycin\(^ {185}\), activation of sirtuin 3 (REF.\(^ {186}\)) and PKA, and modulation of mitochondria-derived ROS\(^ {187}\).

Experimental evidence suggests that supplementation with nitrate might be a novel, safe and inexpensive therapeutic approach for patients with T2DM at an increased

---

**Dietary Approaches to Stop Hypertension (DASH) diet**

A diet rich in fruits, vegetables and low-fat dairy products, that was developed by the nutrition committee of the American Heart Association and has been shown to reduce blood pressure.
risk of developing DKD. To date, few clinical trials have tested the potential beneficial effects of nitrate in patients with T2DM. A small trial in 27 patients with T2DM showed no significant effect of 2 weeks of nitrate supplementation (250 ml beetroot juice daily) on cardio-metabolic functions (that is, blood pressure, endothelial function and insulin sensitivity). Another study that investigated the long-term metabolic effects of low-dose nitrate supplementation (250 mg per day for 24 weeks) in patients with T2DM found no significant difference in glycaemic control between the nitrate (n = 35) and placebo groups (n = 29). The reason for this lack of effect in these two studies, which contrasts with substantial experimental evidence, might be the fact that almost all the participants were receiving metformin treatment, which is known to activate AMPK.

In a mouse model of cardiometabolic disease, no additional beneficial effects on cardiovascular and metabolic parameters were observed when dietary nitrate supplementation was given in combination with metformin, suggesting similar mechanisms of action. A phase II study that investigated the cardiometabolic effects of nitrite therapy (40 mg, three times daily) for 12 weeks in adults with stage 1–2 hypertension, metabolic syndrome and normal kidney function who were not receiving any medications that affect glucose metabolism showed that nitrite gradually lowered blood pressure during the first 8 weeks of treatment (by approximately –10 mmHg), but blood pressure levels started to return to baseline after 10–12 weeks. Hyperinsulinaemic–euglycaemic clamp studies suggested that nitrite supplementation resulted in a trend towards decreased endogenous glucose production and improved insulin sensitivity. Strikingly, a significant improvement in carotid intima media thickness and brachial artery endothelial function was observed after 12 weeks of nitrite therapy.

Kidney effects. Patients with CKD and those with kidney failure have compromised NOS function, reduced NO bioactivity and increased cardiovascular morbidity and mortality. Moreover, a positive association between renal nitrate clearance and kidney function has been observed in patients with CKD. Studies in adult and paediatric patients with kidney failure have shown that peritoneal dialysis and haemodialysis sessions are associated with disturbed NO homeostasis, measured as a reduction in the circulating levels of nitrate, nitrite and cGMP (a marker of NO signalling). Clinical studies are needed to investigate the therapeutic value of restoring NO homeostasis, using nitrate and/or nitrite supplementation, in these vulnerable high-risk patients.

In numerous experimental studies, chronic treatment with inorganic nitrate and nitrite has been associated with therapeutic effects such as attenuation of kidney injury and preservation of kidney blood flow and GFR in models of kidney disease with or without coexistent hypertension and metabolic disease, including models with chronic pharmacological inhibition of NOS, unilateral nephrectomy combined with a high-salt diet, two-kidney one clip, deoxycorticosterone acetate salt, Ang II infusion, ageing and kidney IRI. Based on these studies, several mechanisms have been proposed to contribute to the favourable effects of nitrate and nitrite supplementation. These include dampening of oxidative stress via a reduction in NADPH oxidase activity, increased antioxidant capacity of superoxide dismutase, increased NO bioactivity, a reduction in Ang II sensitivity and type I angiotensin II receptor expression in the renovascular system, dampening of renal sympathetic nerve activity and modulation of immune cell phenotypes and mitochondrial function.

In healthy adults, acute intravenous infusion of nitrite dose-dependently (0.58–5.21 μmol/kg/h) reduced blood pressure compared with placebo, but had no significant effect on GFR measured using 51Cr-EDTA clearance. This blood pressure response was augmented in hypertensive compared with normotensive individuals (mean decreases in systolic blood pressure of 17 mmHg vs 10 mmHg). The researchers showed that the reduction in blood pressure was associated with a decrease in urinary levels of ENaC and aquaporin 2, but the effects of nitrite infusion on fractional sodium excretion were inconsistent (that is, unchanged, decreased or increased). In healthy individuals, the nitrate-mediated effects were not associated with changes in plasma or urine cGMP levels and were not significantly affected by simultaneous inhibition of XOR, ACE or carbonic anhydrase. Moreover, dietary nitrate supplementation (approximately 0.1 mmol/kg/day) for 1 week did not significantly change eGFR (measured using creatinine clearance) compared with placebo in healthy young men.

A systematic review and meta-analysis that investigated various modifiable lifestyle factors showed that higher vegetable intake significantly reduced the risk of CKD. To what extent this effect might be linked to increased intake of nitrate is unknown. To date, no placebo-controlled clinical trial has investigated the effects of chronic nitrate supplementation in patients with kidney disease. However, a crossover study in patients with CKD (stages 2–4) due to hypertensive or diabetic nephropathies showed a significant reduction of blood pressure and renal resistive index 4 h after a single dose of nitrate (300 mg) in hypertensive or diabetic nephropathies. Moreover, a prospective study with a follow-up period of almost 6 years concluded that a habitually high intake of nitrate and/or nitrite from dietary sources was independently associated with a significantly reduced risk of hypertension and CKD.

Taken together, clinical studies have demonstrated that nitrate supplementation is associated with the lowering of blood pressure, which seems to be more pronounced in patients with hypertension. In healthy individuals this effect is not associated with significant changes in kidney function, whereas favourable effects on renal haemodynamics were observed in patients with CKD. Future longer-term, placebo-controlled, randomized trials are needed to determine if supplementation with inorganic nitrate and/or nitrite to restore NO bioactivity could be a beneficial additive treatment to slow the progression of kidney disease and associated cardiovascular and metabolic disorders. Such effects have consistently been reported in experimental studies.
Conclusions and future perspectives

Several decades have passed since the discovery of NO as the elusive endothelium-derived relaxing factor, but some controversies still exist regarding its formation and the true identity of the signalling molecule, as well as its downstream signalling and effector sites in health and disease. NO and other bioactive nitrogen oxide species have pivotal roles in multiple physiological functions, including modulation of the kidney, cardiovascular and metabolic systems. NO is classically derived from l-arginine-dependent NOS isoforms, but can also be formed endogenously via serial reduction steps of inorganic nitrate and nitrite. This nitrate–nitrite–NO pathway, which can be boosted via the diet, is of particular importance in conditions where the activity of the NOS system is reduced or non-functional (that is, hypoxia, ischaemia and low pH). Downstream signalling and functional effects are linked with both cGMP-dependent and -independent mechanisms. Reduced NO bioactivity due to compromised NO generation or increased metabolism has been associated with aging and kidney, cardiovascular and metabolic disorders, which are often coupled with increased generation of ROS leading to oxidative stress. In the kidney, NO is crucially involved in autoregulation and modulation of tubular transport, which may be of importance in the development and progression of hypertension, CKD, ischaemia-reperfusion injury and DKD. Although several experimental studies have demonstrated favourable effects of nitrate and nitrite supplementation on kidney disease and associated complications, these results await further clinical translation. Existing and future novel strategies that increase NO bioactivity and reduce oxidative stress, via both pharmacological and nutritional approaches, may have therapeutic potential to prevent and treat kidney disease and associated cardiometabolic complications. One of the challenges with such novel drug candidates is to optimize their spatial and temporal delivery to achieve the desired effects without any unwanted disturbances in normal physiological redox signalling.

Published online 1 June 2021

1. GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 395, 709–733 (2020).

2. Global Burden of Metabolic Risk Factors for Chronic Diseases Collaboration. Cardiovascular disease, chronic kidney disease, and diabetes mortality burden of cardiometabolic risk factors from 1980 to 2010: a comparative risk assessment. Lancet Diabetes Endocrinol. 2, 634–647 (2014).

3. Whaley-Connell, A. & Sowers, J. R. Basic science: pathophysiology, the cardiorenal metabolic syndrome. J. Am. Soc. Hypertens. 8, 604–606 (2014).

4. Rangaswami, J. et al. Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation 139, e840–e878 (2019).

5. Aron-Wisnewsky, J. & Clement, K. The gut microbiome, diet, and links to cardiometabolic and chronic disorders. Nat. Rev. Nephrol. 12, 169–181 (2016).

6. Yang, T., Richards, E. M., Pepine, C. J. & Raizada, M. K. The gut microbiota and the brain-gut-kidney axis in biological tissues. Enzyme-independent formation of nitric oxide in humans: measurements in expelled air. Proc. Natl Acad. Sci. USA 87, 1620–1624 (1990).

7. Marsden, P. A. et al. Molecular cloning and characterization of human endothelial nitric oxide synthase. FEBS Lett. 307, 287–293 (1992).

8. Xie, Q. W. et al. Cloning and characterization of inducible nitric oxide synthase from mouse macrophages. Science 256, 225–228 (1992).

9. Chartrain, N. A. et al. Molecular cloning, structure, and chromosomal localization of the human inducible nitric oxide synthase gene. J. Biol. Chem. 269, 6765–6772 (1994).

10. Forstermann, U. & Sessa, W. C. Nitric oxide synthases: regulation and function. Eur. Heart J. 33, 829–837 (2012).

11. Moncada, S., Palmer, R. M. G. & Higgs, E. A. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol. Rev. 43, 109–142 (1991).

12. Papapetropoulos, A., Hobs, A. J. & Topouzis, S. Extending the translational potential of targeting NO/cGMP-regulated pathways in the CVS. Br. J. Pharmacol. 172, 1537–1544 (2015).

13. Lima, B., Forrester, M. T., Hess, D. T. & Stamler, J. S. Nitrosylation in cardiovascular signaling. Circ. Res. 102, 635–645 (2008).

14. Isciphioupolos, H. Protein tyrosine nitration — an update. Arch. Biochem. Biophys. 484, 117–121 (2009).

15. Villacorta, L., Gao, Z., Schopfer, F. J., Freeman, B. A. & Chen, Y. E. Nitric-fatty acids in cardiovascular regulation. Current diseases and molecular mechanisms. Front. Biosci. 21, 873–889 (2016).

16. Kleschyov, A. L. The NO-heme signaling hypothesis. Free Radic. Biol. Med. 112, 544–552 (2017).

17. Vederovski, V. P., Mordvintsev, P. I., Malenkov, I. V. & Vanin, A. F. Similarity between the vasorelaxing activity of dimethyliron cysteine complexes and endothelium-derived relaxing factor. Eur. J. Pharmacol. 211, 313–317 (1992).

18. Stamler, J. S., Singel, D. J. & Loscalzo, J. Biochemistry of nitric oxide and its derived bioactive forms. Science 258, 1899–1902 (1992).

19. Moller, M. N. et al. Detection and quantification of nitric oxide–derived oxidants in biological systems. J. Biol. Chem. 294, 14776–14802 (2019).

20. Bolden, C., King, S. B. & Kim-Shapiro, D. B. Reactions between nitrosuperoxide and heme proteins. Free Radic. Biol. Med. 99, 418–425 (2016).

21. Murphy, M. E. & Sies, H. Reversible conversion of nitric oxide into nitrite. Nat. Rev. Pharmacol. 8, 10860–10866 (1991).

22. Beckman, J. S., Beckman, T. W., Chen, J., Marshall, P. A. & Freeman, B. A. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc. Natl Acad. Sci. USA 87, 1620–1624 (1990).

23. Hess, E. H. & Dietrich, V. M. Regulation of eNOS enzyme activity by posttranslational modification. Curr. Pharm. Des. 20, 3503–3513 (2014).

24. Sharma, N. M. & Patel, K. P. Post-translational regulation of neuronal nitric oxide synthase: implications for sympathoexcitatory states. Expert Opin. Ther. Targets 21, 11–22 (2017).

25. Hess, D. T. & Stamler, J. S. Regulation by s-nitrosylation of protein post-translational modification. J. Biol. Chem. 287, 4411–4418 (2012).

26. Mount, P. F., Kemp, B. E. & Power, D. A. Regulation of endothelial and myocardial NO synthesis by multiple s-NOS phosphorylation. J. Mol. Cell. Cardiol. 42, 271–279 (2007).

27. Mount, P. F. & Power, D. A. Nitric oxide in the kidney: functions and regulation of synthesis. Acta Physiol. 187, 443–446 (2006).

28. Zarama, R., Vodovotz, Y. & Billir, T. R. Inducible nitric oxide synthase and inflammatory diseases. Mol. Med. 6, 347–375 (2000).

29. Baylis, C. Nitric oxide deficiency in chronic kidney disease. Am. J. Physiol. Renal Physiol. 294, F1–F9 (2008).

30. Baylis, C. Arginine, arginin analogs and nitric oxide production in chronic kidney disease. Nat. Clin. Pract. Nephrol. 2, 209–220 (2006).

31. Farah, C., Michel, L. Y. M. & Balligand, J. L. Nitric oxide signalling in cardiovascular health and disease. Nat. Rev. Cardiol. 15, 292–316 (2018).

32. Eissa, N. T. et al. Alternative splicing of human inducible nitric oxide synthase mRNA: tissue-specific regulation and inducible nitric oxide synthase. J. Biol. Chem. 271, 27184–27187 (1996).

33. Saur, D., Paehge, H., Schudisziana, V. & Allescher, H. D. Distinct expression of splice variants of neuronal nitric oxide synthase in the human gastrointestinal tract. Gastroenterology 118, 849–858 (2000).

34. Lu, D. et al. Salt sensitive splice variant of nNOS expressed in the macula densa cells. Am. J. Physiol. Renal Physiol. 298, F1455–F1471 (2010).

35. Jarry, A. et al. Expression of NOSI and soluble guanylyl cyclase by human kidney epithelial cells: morphological evidence for an autocrine/paracrine action of nitric oxide. Kidney Int. 64, 170–180 (2003).

36. Goloponsky, M. S., Brodsky, S. V. & Nouri, E. Nitric oxide in acute renal failure. Nos versus Nos. Kidney Int. 61, 855–861 (2002).

37. Yoo, K. H., Thornhill, B. A., Forbes, M. S. & Chevalier, R. L. Inducible nitric oxide synthase modulates hydroperoxidation following partial or complete unilateral ureteral obstruction in the neonatal mouse. Am. J. Physiol. Renal Physiol. 298, F62–F71 (2010).

38. Heemskerk, S. et al. Upregulation of renal inducible nitric oxide synthase during human endotoxemia and sepsis is associated with proximal tubule injury. Clin. J. Am. Soc. Nephrol. 1, 855–862 (2006).

39. Udi, S. et al. Dual inhibition of NO-cGMP and CB1 receptor and inducible NOS attenuates obesity-induced chronic kidney disease. Br. J. Pharmacol. 177, 110–127 (2020).
Rhodes, P. et al. The L-arginine–nitric oxide pathway is the major source of plasma nitrite in fasted humans. Biochim. Biophys. Res. Commun. 209, 590–596 (2004).

Lundberg, J. O. & Govoni, M. Inorganic nitrate is a possible source for systemic generation of nitric oxide. Free Radic. Biol. Med. 57, 595–600 (2014).

Qin, L. et al. Sialin (SCLT17S) functions as a nitrate transporter in the plasma membrane. Proc. Natl Acad. Sci. USA 109, 15344–15349 (2012).

Edwards, D. A., Fletcher, K. & Rowlands, E. N. Antagonism between perchlorate, iodide, thiocyanate, and nitrate for secretion in human saliva, analog with the duct of the thyroid. Lancet 366, 498–499 (2005).

Duncan, C. et al. Chemical generation of nitrite in vivo with a high-uncoupling adenine nucleotide circulation. Nat. Med. 1, 546–551 (1995).

Lundberg, J. O. & Weitzberg, E. Biology of nitrogen oxides in the gastrointestinal tract. Gut 61, 612–619 (2013).

Helms, C. C., Liu, X. & Kim-Shapiro, D. B. Recent insights into endogenous precursors of nitric oxide in blood. Biol. Chem. 398, 319–329 (2016).

Blood, A. A. The medicinal chemistry of nitrite as a source of nitric oxide signaling. Curr. Top. Med. Chem. 17, 1758–1768 (2017).

Webb, A. et al. Reduction of nitrite to nitric oxide during ischemia protects against myocardial ischemia-reperfusion injury. Proc. Natl Acad. Sci. USA 101, 15638–15648 (2004).

Gautier, C., van Faassen, E., Mikula, I., Martasek, P. & Gibbons, M. Endothelial nitric oxide synthase reduces nitric oxide to NO under anoxia. Biochem. Biophys. Res. Commun. 341, 816–821 (2006).

Castelo-Branco, P., Almeida, C., Crook, Z. & Poyton, R. O. Mitochondrial cytochrome oxidase produces nitric oxide under hypoxic conditions: implications for oxygen sensing and hypoxic signaling. Annu. Rev. Physiol. 71, 157–179 (2009).

Narayanan, S. P. & Caldwell, R. B. Arginase: a key enzyme in the regulation of arginine steal? Curr. Opin. Pharmacol. 8, 15049–15054 (2013).

Baitha, A. & Munzel, T. Organic nitrate therapy, nitrate tolerance, and nitrate-induced endothelial dysfunction: emphasis on redox biology and oxidative stress. Antioxid. Redox Signal. 23, 899–942 (2015).

Antoniades, C. et al. Angiotensin-converting enzyme 2 and angiotensin 1–7 novel therapeutic targets. Expert Opin. Pharmacother. 11, 413–426 (2010).

Barnes, M. & Briscoes, E. J. Clinical use of inhaled nitric oxide: local and systemic applications. Free Radic. Biol. Med. 152, 422–431 (2020).

Ruan, S. Y. et al. Inhaled nitric oxide therapy and risk of renal dysfunction: a systematic review and meta-analysis of randomized trials. Crit. Care 19, 157 (2015).

Dai, X.-J. & Munzel, T. Organic nitrate therapy, nitrate tolerance, and nitrate-induced endothelial dysfunction: emphasis on redox biology and oxidative stress. Antioxid. Redox Signal. 23, 899–942 (2015).

Antoniades, C. et al. Angiotensin-converting enzyme 2 and angiotensin 1–7 novel therapeutic targets. Expert Opin. Pharmacother. 11, 413–426 (2010).

Barnes, M. & Briscoes, E. J. Clinical use of inhaled nitric oxide: local and systemic applications. Free Radic. Biol. Med. 152, 422–431 (2020).

Ruan, S. Y. et al. Inhaled nitric oxide therapy and risk of renal dysfunction: a systematic review and meta-analysis of randomized trials. Crit. Care 19, 157 (2015).

Daiber, A. & Munzel, T. Organic nitrate therapy, nitrate tolerance, and nitrate-induced endothelial dysfunction: emphasis on redox biology and oxidative stress. Antioxid. Redox Signal. 23, 899–942 (2015).

Antoniades, C. et al. Angiotensin-converting enzyme 2 and angiotensin 1–7 novel therapeutic targets. Expert Opin. Pharmacother. 11, 413–426 (2010).

Barnes, M. & Briscoes, E. J. Clinical use of inhaled nitric oxide: local and systemic applications. Free Radic. Biol. Med. 152, 422–431 (2020).

Ruan, S. Y. et al. Inhaled nitric oxide therapy and risk of renal dysfunction: a systematic review and meta-analysis of randomized trials. Crit. Care 19, 157 (2015).
123. Szabo, C. Roles of hydrogen sulfide in the pathogenesis of diabetes mellitus and its complications. Antioxid. Redox Signal. 17, 68–80 (2012).
124. Kasinath, B. S., Feilers, D. & Lee, H. J. Hydrogen sulfide as a regulator of bradykinin in kidney health and disease. Biochem. Pharmacol. 149, 24–91 (2018).
125. Li, Z., Polhemus, D. J. & Lefer, D. J. Evolution of hydrogen sulfide: Biochemical, biophysical, and toxicological perspectives to treat cardiovascular disease. Circ. Res. 123, 590–600 (2018).
126. Altyaeva, Z., Yang, G. & Wang, R. Crossstalk between hydrogen sulfide and nitric oxide in endothelial cells. J. Cell. Mol. Med. 17, 879–888 (2013).
127. Coletta, C. et al. Hydrogen sulfide and nitric oxide are mutually dependent in the regulation of angiogenesis and endogenous vasorelaxation. Proc. Natl. Acad. Sci. USA 109, 9161–9166 (2012).
128. Pardun, S. et al. Hydrogen sulfide stimulates xanthine oxidase, a potential contributor to recurrent nitrate washout and formation of NO. Redox Biol. 34, 101447 (2020).
129. Bucci, M. et al. Hydrogen sulfide is an endogenous inhibitor of phosphodiesterase activity. Antioxid. Thirom. Vasc. Biol. 30, 198–204 (2010).
130. Cortese-Krott, M. M. et al. Key bioactive reaction products of the NOS/HS interaction are S-nitrosothiol species, polysulfinyls, and nitrosyls. Proc. Natl. Acad. Sci. USA 112, E4651–E4660 (2015).
131. Kukreja, R. C., Salloum, F. N. & Dax, A. Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection. J. Am. Coll. Cardiol. 59, 1921–1927 (2012).
132. Brown, M. L., Goudard, J. D. & Webb, D. J. Potential therapeutic role of phosphodiesterase type 5 inhibition in hypertension and chronic kidney disease. J. Hypertens. 31, 1436 (2013).
133. Rodriguez-Iturbe, B. et al. Early treatment with cGMP phosphodiesterase inhibitor ameliorates progression of diabetic kidney disease. Kidney Int. 83, 1998–2004 (2013).
134. Scheele, W. et al. Phosphodiesterase type 5 inhibition and clinical applications 20 years after sildenafil discovery. Curr. Opin. Pharmacol. 16, 95–104 (2015).
135. Lim, S., Bae, J. H., Kwon, H. S. & Nauck, M. A. Cyclic guanosine monophosphate signaling and mitochondrial integrity in diabetic nephropathy. Indian J. Nephrol. 30, 15–22 (2013).
136. Maschio, G. et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of kidney disease. N. Engl. J. Med. 343, 355–394 (2005).
137. Jackson, J. K., Patterson, A. J., MacDonald-Wicks, L. K., Oldmeadow, C. B. & McEvoy, M. A. The role of inorganic nitrate and nitrite as risky factors: a systematic review and meta-analysis of human evidence. Nutr. Rev. 64, 355–394 (2016).
138. Bae, S., Kim, S. R., Kim, M. N., Shim, W. J. & Park, M. H. Dietary nitrate improves vascular function in endothelial nitric oxide synthase-deficient mice. Proc. Natl. Acad. Sci. USA 107, 1716–17220 (2010).
139. Park, S. M. Impact of cardiovascular disease and risk factors on nephron filtration and diabetic kidney disease. N. Engl. J. Med. 365, 3459–3468 (2011).
140. Gefter, S. R. et al. Dietary nitrate and nitrite in cardiovascular and metabolic diseases. J. Intern. Med. 3. 279, 315–356 (2016).
141. Groll, M., Stuehler, M. et al. Potential therapeutic value of dietary nitrate and nitrite in heart failure patients with preserved EF (SOCRATES-PRESERVED) study. Circ. Res. 125, 1883–1893 (2020).
142. Kawamura, M. et al. Inorganic nitrate promotes glucose uptake and oxidative catabolism in white adipose tissue through the XOR-catalyzed nitric oxide pathway. Diabetes 69, 893–901 (2020).
143. Singamsetty, S. et al. Inorganic nitrate improves components of the metabolic syndrome independent of weight change in a murine model of obesity and insulin resistance. J. Physiol. 593, 3135–3145 (2015).
144. Kamga, P. C. et al. Nitrate activates protein kinase A in normoxia to mediate mitochondrial fusion and tolerance to ischemia/reperfusion. Cardiovasc. Res. 107, 57–68 (2015).
145. Moretti, C. H. et al. Dietary nitrate extends lifespan and prevents age-related locomotor decline in the fruit fly. Free. Radic. Biol. Med. 165, 205–217 (2021).
146. Bahadoran, Z., Ghasemi, A., Miriman, P. A., Azizi, F. & Hadaegh, F. Beneficial effects of inorganic nitrate/nitrite type 2 diabetes complications. Nutr. Metab. 12, 16 (2015).
147. Shemer, E. et al. Effect of dietary nitrate on blood pressure, endothelial function, and insulin sensitivity in type 2 diabetes. Free. Radic. Biol. Med. 60, 89–97 (2013).
148. Bahadoran, Z. et al. Effect of inorganic nitrate on metabolic parameters in patients with type 2 diabetes. A 24-week randomized double-blind placebo-controlled clinical trial. Nitric Oxide 107, 58–65 (2021).
149. Zhou, G. et al. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108, 1167–1174 (2001).
150. Cordero-Herrera, I. et al. Head-to-head comparison of inorganic nitrate and metformin in a mouse model of cardiometabolic disease. Nitric Oxide 97, 48–56 (2020).
151. Hughan, K. S. et al. Effects of oral sodium nitrite on blood pressure, insulin sensitivity, and iminolipid atheroma thickening in aortic arch vessel. J. Med. 146, 1456–1462 (1993).
152. Moret, C. L. et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of kidney disease. N. Engl. J. Med. 343, 749–756 (2000).
153. Sacks, F. M. et al. Effects of blood pressure of reduced dietary sodium and the dietary approaches to stop hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N. Engl. J. Med. 344, 3–10 (2001).
154. Appel, L. J. et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N. Engl. J. Med. 336, 1117–1124 (1996).
Peritoneal dialysis impairs nitric oxide homeostasis and may predispose infants with low systolic blood pressure to cerebral ischemia. *Nitr. Oxid.* 58, 1–9 (2016).

Carlstrom, M. et al. Plasma nitrate/nitrite removal by peritoneal dialysis might predispose infants with low blood pressure to cerebral ischemia. *Clin. Kidney J.* 8, 215–218 (2015).

Heredia Martínez, A. et al. Removal of nitrate and nitrite by hemodialysis in end-stage renal disease and by sustained low-efficiency dialysis in acute kidney injury. *Nitr. Oxid.* 98, 33–40 (2020).

Carlstrom, M. et al. Dietary nitrate attenuates oxidative stress, prevents cardiac and renal injuries, and reduces blood pressure in salt-induced hypertension. *Cardiovasc. Res.* 89, 574–585 (2011).

Gao, X. et al. NADPH oxidase in the renal microvasculature is a primary target for blood pressure-lowering effects by inorganic nitrate and nitrite. *Hypertension* 65, 161–170 (2015).

Guimarães, D. D. et al. Dietary nitrate reduces blood pressure in rats with angiotensin II-induced hypertension via mechanisms that involve reduction of sympathetic hyperactivity. *Hypertension* 73, 839–848 (2019).

Hezel, M. et al. Dietary nitrate improves age-related hypertension and metabolic abnormalities in rats via modulation of angiotensin II receptor signaling and inhibition of superoxide generation. *Free Radic. Biol. Med.* 99, 87–98 (2016).

Tripatara, P. et al. Nitrate-derived nitric oxide protects the rat kidney against ischemia/reperfusion injury in vivo: role for xanthine oxidoreductase. *J. Am. Soc. Nephrol.* 18, 570–580 (2007).

Yang, T. et al. Dietary nitrate attenuates renal ischemia-reperfusion injuries by modulation of immune responses and reduction of oxidative stress. *Redox Biol.* 15, 320–330 (2017).

Rosenbaek, J. B. et al. Effect of sodium nitrite on renal function and sodium and water excretion and brachial and central blood pressure in healthy subjects: a dose-response study. *Am. J. Physiol. Renal Physiol.* 313, F378–F387 (2017).

Rosenbaek, J. B. et al. Effects of sodium nitrite on renal function and blood pressure in hypertensive vs. healthy study participants: a randomized, placebo-controlled, crossover study. *J. Hypertens.* 36, 666–679 (2018).

Rosenbaek, J. B., Pedersen, E. B. & Bech, J. N. The effect of sodium nitrite infusion on renal function, brachial and central blood pressure during enzyme inhibition by allopurinol, enalapril or acetazolamide in healthy subjects: a randomized, double-blinded, placebo-controlled, crossover study. *BMC Nephrol.* 19, 244 (2018).

Carpentier, A., Stragier, S., Brejeon, C. & Poortmans, J. R. Nitrate supplementation, exercise, and kidney function: are there detrimental effects? *Med. Sci. Sports Exerc.* 47, 1519–1522 (2015).

Kelly, J. T. et al. Modifiable lifestyle factors for primary prevention of CKD: a systematic review and meta-analysis. *J. Am. Soc. Nephrol.* 32, 239–253 (2021).

Kemmner, S. et al. Dietary nitrate load lowers blood pressure and renal resistive index in patients with chronic kidney disease: a pilot study. *Nitr. Oxid.* 64, 7–15 (2017).

Bahadoran, Z. et al. Association between dietary intakes of nitrate and nitrite and the risk of hypertension and chronic kidney disease: Tehran lipid and glucose study. *Nutrients* 8, 811 (2016).

M.C. sincerely thanks all co-authors of the original articles from their groups, which are highlighted in this Review. A special thanks to E. Weitzberg and J. O. Lundberg (Karolinska Institutet) for valuable comments on the manuscript, and to S. McCann Haworth (Karolinska Institutet) for language editing before submission. M.C. receives research support from the Swedish Research Council (2016-01581, 2020-01645), the Swedish Heart and Lung Foundation (20170124, 20180568), NovoNordisk (2019#0055026) and by EFSD/Lilly European Diabetes Research Programme (2018#97012). Stockholm County Council Research Funding [ALF, 2019:014], as well as Research Funds (2-560-2015) and KID funding (2-5707/2013 & 2-1930/2016) from the Karolinska Institutet, Stockholm, Sweden.

**Author contributions**  M.C. researched the data for the article, wrote the manuscript and reviewed and edited it before submission.

**Competing interest**  The author declares no competing interests.

**Peer review information**  *Nature Reviews Nephrology* thanks Johannes Stegbauer, Andrew Webb and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

**Publisher’s note**  Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.